Forge Medical, Developer and Manufacturer of VasoStat Hemostasis Device, Enters into Commercialization Agreement With Lokai Medical

News

Submitted on Mon, 04/23/2018 - 14:45
Vasostat

BETHLEHEM, PENNSYLVANIA, April 22, 2018 - Forge Medical, a U.S. developer of innovative solutions for transradial and transpedal hemostasis and manufacturer of the VasoStat® Hemostasis Device, announced that the company has entered into a commercialization agreement with Lokai Medical. Lokai Medical, based in Phoenix, Arizona is a specialty distributor of coronary/ cardiovascular and interventional devices throughout the United States. Timothy Clark, M.D., CEO of Forge Medical, said: “Transradial and transpedal approaches are becoming increasingly adopted by interventional cardiologists, interventional radiologists, and vascular surgeons. These clinicians demand an effective solution for puncture site management with rapid and patent hemostasis and optimal patient comfort. We are pleased to partner with the talented team at Lokai Medical to provide this unique and innovative hemostasis device to ever growing numbers of U.S. clinicians and hospitals.”

 

Vasostat